The massive increase in funding for malaria control in the past decade has led to a sharp rise in the procurement of artemisinin combination therapies (ACTs)—the recommended first-line treatment for uncomplicated Plasmodium falciparum malaria. However, availability of these life-saving drugs varies between countries, and positive health outcomes need not only ACTs to be available at all levels of the health-care system, but also health workers to prescribe them according to national guidelines and patients to adhere to their treatment regimens.